Insulet Corporation
看多

Two healthcare leaders, which one is best to own?

46
PODD & DXCM are leading the sectors recovery.

Both are in the Medical Products Industry for diabetes.

Insulent (PODD) normally outperforms DexCom (DXCM) during and after a correction. Then, when they are in sustained uptrends, DXCM outperforms.

For the recent correction, PODD has a -45% deep base while DXCM has a -58%.

PODD bottmed 4 weeks before DXCM, but DXCM has rallied +74% and PODD +65% since.

So, it really depends on your strategy. If you are looking for aplha then DXCM is the stock for you but, if you prefer low beta then PODD is better.

Remember that aplha plays in both ways!

Which are you trading?

I'll trade the first that makes a new high.

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。